Skip to main content

Table 1 Clinical features and baseline plasma lipid concentrations of the two groups of subjects with primary hypercholesterolemia (HCH) treated with BBR/P/RR or EZE for six months

From: Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment

 

BBR/P/RR

EZE

P

Males/Females

62/90

31/45

 

Age (years)

57.3 ± 12.1

58.3 ± 12.3

NS

BMI (kg/m2)

23.9 ± 2.9

23.5 ± 2.8

NS

Arterial hypertension

30.2%

31.5%

NS

Carotid atherosclerosis*

26.3, 48.0, 3.9%

31.5, 51.3, 3.9%

NS

TC (mmol/L)

7.63 ± 0.50

7.72 ± 0.49

NS

LDL-C (mmo/L)

5.36 ± 0.48

5.36 ± 0.52

NS

HDL-C (mmo/L)

1.55 ± 0.35

1.57 ± 0.34

NS

non-HDL-C (mmol/L)

6.07 ± 0.54

6.15 ± 0.55

NS

TG (mmol/L)†

1.46 (1.22-1.90)

1.67 (1.24-2.12)

NS

  1. *Percent of subjects with increased intima-media thickness, with fibrous-calcific plaques with less than 30% stenosis and with fibrous-calcific plaques with 30-40% stenosis, respectively. †Median (interquartile range). NS: not significant.
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X